Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. Issue 1 (January 2015)

• Record Type: Journal Article
• Authors: Falantes, Jose; Delgado, Regina García; Calderón-Cabrera, Cristina; Márquez-Malaver, Francisco J.; Valcarcel, David; de Miguel, Dunia; Bailén, Alicia; Bargay, Joan; Bernal, Teresa; González-Porras, Jose R.; Tormo, Mar; Ramos, Fernando; Andreu, Rafael; Xicoy, Blanca; Nomdedeu, Benet; Brunet, Salut; Sánchez, Joaquín; Jurado, Antonio Fernández; Bonanad, Santiago; Pérez-Simón, Jose Antonio; Sanz, Guillermo; for the Spanish Group of Myelodysplastic Syndromes (GESMD)
• Is Part Of: Leukemia research. Volume 39:Issue 1(2015:Jan.)
• Page Start: 52
• Page End: 57
• Publication Date: 2015-01
• Subjects: Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2014.10.004
• Languages: English
• ISSNs: 0145-2126

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Two scores identify lower-risk patients with survival similar to high-risk patients.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Achieving response to azacitidine in these patients appears to impact on survival.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Thrombocytopenia is the most important prognostic parameter in lower-risk MDS.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">This analysis supports a prospective intervention in these poor risk patients.</p> </list-item> </list> </p> </sec> </abstract>